160 related articles for article (PubMed ID: 21371181)
1. A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
Teitel J; Berntorp E; Dolan G; Fischer K; Gringeri A; Kessler C; Lambert T; Leissinger C; Nemes L; Shima M
Haemophilia; 2011 May; 17(3):516-21. PubMed ID: 21371181
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis in haemophilia patients with inhibitors.
Leissinger CA
Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
[TBL] [Abstract][Full Text] [Related]
3. Complete immunotolerance induction after FEIBA prophylaxis in a haemophilia A patient with high-titre inhibitor.
Nanishi E; Ohga S; Doi T; Ishimura M; Ihara K; Takada H; Shima M; Hara T
Haemophilia; 2012 May; 18(3):e75-7. PubMed ID: 22404696
[No Abstract] [Full Text] [Related]
4. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
Valentino LA
Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
[TBL] [Abstract][Full Text] [Related]
5. The perspective of patients with haemophilia with inhibitors and their care givers: preferences for treatment characteristics.
Brown TM; Pashos CL; Joshi AV; Lee WC
Haemophilia; 2011 May; 17(3):476-82. PubMed ID: 21091851
[TBL] [Abstract][Full Text] [Related]
6. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents.
Mehta R; Parameswaran R; Shapiro AD
Haemophilia; 2006 Dec; 12 Suppl 6():54-61. PubMed ID: 17123395
[TBL] [Abstract][Full Text] [Related]
7. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series.
Ettingshausen CE; Kreuz W
Haemophilia; 2010 Jan; 16(1):90-100. PubMed ID: 19878335
[TBL] [Abstract][Full Text] [Related]
8. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations.
Perry D; Berntorp E; Tait C; Dolan G; Holme PA; Laffan M; Lassila R; Mumford A; Pasi J; Wilde J; Will A; Yee TT
Haemophilia; 2010 Jan; 16(1):80-9. PubMed ID: 19780845
[TBL] [Abstract][Full Text] [Related]
9. How I treat inhibitors in haemophilia.
Makris M; Hay CR; Gringeri A; D'Oiron R
Haemophilia; 2012 Jul; 18 Suppl 4():48-53. PubMed ID: 22726083
[TBL] [Abstract][Full Text] [Related]
10. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
Valentino LA
Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
[TBL] [Abstract][Full Text] [Related]
11. When should prophylaxis therapy in inhibitor patients be considered?
Young G; Auerswald G; Jimenez-Yuste V; Konkle BA; Lambert T; Morfini M; Santagostino E; Blanchette V
Haemophilia; 2011 Sep; 17(5):e849-57. PubMed ID: 21418444
[TBL] [Abstract][Full Text] [Related]
12. Importance of rapid bleeding control in haemophilia complicated by inhibitors.
Berntorp E
Haemophilia; 2011 Jan; 17(1):11-6. PubMed ID: 20565546
[TBL] [Abstract][Full Text] [Related]
13. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition.
Berntorp E; Collins P; D'Oiron R; Ewing N; Gringeri A; Négrier C; Young G
Haemophilia; 2011 Jan; 17(1):e202-10. PubMed ID: 20825500
[TBL] [Abstract][Full Text] [Related]
14. Meeting unmet needs in inhibitor patients.
Blanchette VS; Manco-Johnson MJ
Haemophilia; 2010 May; 16 Suppl 3():46-51. PubMed ID: 20586802
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors.
Leissinger CA; Becton DL; Ewing NP; Valentino LA
Haemophilia; 2007 May; 13(3):249-55. PubMed ID: 17498073
[TBL] [Abstract][Full Text] [Related]
16. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues.
Aledort LM
Haemophilia; 2008 Jan; 14(1):39-43. PubMed ID: 17961169
[TBL] [Abstract][Full Text] [Related]
17. Successful prophylaxis using activated prothrombin complex concentrates (aPCC) in a severe haemophilia A patient with inhibitor previously unresponsive to on-demand daily infusions of aPCC.
Furukawa S; Nogami K; Ogiwara K; Yada K; Shima M
Haemophilia; 2017 Sep; 23(5):e481-e484. PubMed ID: 28771891
[No Abstract] [Full Text] [Related]
18. Clinical issues in inhibitors.
Astermark J; Santagostino E; Keith Hoots W
Haemophilia; 2010 Jul; 16 Suppl 5():54-60. PubMed ID: 20590857
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference.
Berntorp E; Shapiro A; Astermark J; Blanchette VS; Collins PW; Dimichele D; Escuriola C; Hay CR; Hoots WK; Leissinger CA; Negrier C; Oldenburg J; Peerlinck K; Reding MT; Hart C
Haemophilia; 2006 Dec; 12 Suppl 6():1-7. PubMed ID: 17123387
[TBL] [Abstract][Full Text] [Related]
20. Can we consider discontinuing primary prophylaxis in adults with severe haemophilia?
Fischer K
Haemophilia; 2008 Jul; 14 Suppl 4():10. PubMed ID: 18494687
[No Abstract] [Full Text] [Related]
[Next] [New Search]
